Abstract: The present invention relates to a new combination comprising a therapeutically effective amount of an anti-IL1? antibody or an antigen-binding fragment thereof and at least one anti-diabetic agent.

Abstract: TNF.alpha. antagonist compounds and methods of using the same are disclosed. The compounds comprise a molecular surface that is substantially similar to at least one molecular surface of human TNF.alpha.. The compounds bind to TNF receptors but do not produce the same biological effect as that which occurs when TNF.alpha. binds to a TNF receptor. Methods of inhibiting tumor necrosis factor activity are disclosed. The methods comprise the step of contacting tumor necrosis factor alpha with a TNF.alpha. antagonist. Methods of treating individuals suspected of suffering from or being susceptible to a disease or disorder mediated by tumor necrosis factor-alpha activity are disclosed. The methods comprise the step of administering to said individual a therapeutically effective amount of a TNF.alpha. antagonist.